[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369011-105":59,"doc-detail-369011-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","challenges-and-opportunities-for-oncology-drug-repurposing-informed-by-synthetic-lethality","Challenges and opportunities for oncology drug repurposing informed by synthetic lethality","","Synthetic lethality provides a strategy to treat cancers by exploiting vulnerabilities created by specific loss-of-function alterations in tumor suppressor or driver genes. Using genome-wide CRISPR/Cas9 knockout viability screens from the Cancer Dependency Map, the study identifies clinically relevant synthetic lethal interactions via mutual exclusivity in patient tumors. Drug sensitivity data are integrated to propose inhibitors that can phenocopy genetic knockout effects. Only a small subset of pharmacological inhibitors reproduce matched genetic perturbations, highlighting differences between genetic and drug perturbations. The work clarifies how to map actionable targets for precision oncology.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/challenges-and-opportunities-for-oncology-drug-repurposing-informed-by-synthetic-lethality/369011/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/challenges-and-opportunities-for-oncology-drug-repurposing-informed-by-synthetic-lethality/369011.png","ImageObject",300,407,{"name":92,"@type":93},"mieayamfan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the core idea behind synthetic lethality in cancer therapy?","Question",{"text":113,"@type":114},"Synthetic lethality targets a genetic interaction where loss of either gene alone is tolerated, but combined disruption causes cell death. In oncology, this is often implemented by inhibiting a protein that is lethal only in cancer cells carrying a specific loss-of-function alteration.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were clinically relevant synthetic lethal interactions identified in the study?",{"text":118,"@type":114},"Genome-wide CRISPR/Cas9 knockout viability screens from the Cancer Dependency Map were analyzed, and clinical relevance was assessed in patient tumors using mutual exclusivity patterns.",{"name":120,"@type":111,"acceptedAnswer":121},"Why do pharmacological inhibitors often fail to match CRISPR knockout effects?",{"text":122,"@type":114},"The study finds that only a small fraction of drugs induce effects similar to genetic knockout of matched targets. This discrepancy indicates fundamental differences between pharmacological and genetic perturbations in cancer models.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},369011,1790212220,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962090893677,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","npj | systems biology and applications Article  \n\n| Published in partnership with the Systems Biology Institute |  | |\n| --- | --- | --- |\n| [https://doi.org/10.1038/s41540-025-00618-7](https://doi.org/10.1038/s41540-025-00618-7) |  |  |\n| Challengesand opportunitiesfor oncology drug repurposing informed by synthetic lethality\u003Cbr> Check for updates |  |  |\n| Michael Vermeulen1 , Andrew W. Craig2,3 & Tomas Babak1,4  |  |  |\n| Although two-thirds of cancers arise from loss-of-function mutations in tumor suppressor genes, there are few approved targeted therapies linked to these alterations. Synthetic lethality offers a promising strategy to treat such cancers by targeting vulnerabilities unique to cancer cells with these mutations. To identify clinically relevant synthetic lethal interactions, we analyzed genome-wide CRISPR/Cas9 knock-out (KO) viability screens from the Cancer Dependency Map and evaluated their clinical relevance in patient tumors through mutual exclusivity, a pattern indicative of synthetic lethality. Indeed, we found signiﬁcant enrichment of mutual exclusivity for interactions involving cancer driver genes compared to non-driver mutations. To identify therapeutic opportunities, we integrated drug sensitivity data to identify inhibitors that mimic the effects of CRISPR-mediated KO. This approach revealed potential drug repurposing opportunities, including BRD2 inhibitors for bladder cancers with ARID1A mutations and SIN3A-mutated cell lines showing sensitivity to nicotinamide phosphoribosyltransferase (NAMPT) inhibitors. However, we discovered that pharmacological inhibitors often fail to phenocopy KO of matched drug targets, with only a small fraction of drugs inducing similar effects. This discrepancy reveals fundamental differences between pharmacological and genetic perturbations, emphasizing the need for approaches that directly assess the interplay of loss-of-function mutations and drug activity in cancer models. |  |  |\n| Synthetic lethality (SL) provides a compelling framework for developing cancer therapies tailored to the speciﬁc genetic proﬁles of individual patient tumors. SL relies on the genetic interaction between two genes, where disruption of either gene alone is tolerated, but their simultaneous disruption leads to cell death. Applying this strategy in oncology usually involves pharmacologically targeting a protein whose inhibition is lethal to cancer cells harboring a speciﬁc loss-of-function (LoF) mutation in a partnering gene, but spare healthy cells without these mutations (Supplementary Fig. 1A) . The appeal of exploiting SL lies in the potential to increase treatment efﬁcacy, minimize adverse effects and expand the range of actionable therapeutic targets, particularly tumor suppressor genes(TSGs)that currently lack effective therapies1,2. An exemplar ofthis approach is the use of poly (ADP-ribose) polymerase (PARP) inhibitors, which harness SL to exploit DNA repair deﬁciencies in homologous recombination deﬁcient (HRD) cancers, commonly driven by LoF alterations in BRCA1 and BRCA23. Generating over $3 billion annually, PARP inhibitors have become standard ofcare treatment for several HRD | cancers, and are increasingly used in combination therapies that prove the value of exploiting the potential of SL-driven oncology.\u003Cbr>Despite the success of PARP inhibitors, broader clinical adoption of additional SL drugs has not been as effective as predicted and is limited to a handful of clinical-stage developments, none of which have yet been approved. However, progress may have been limited by a lack of systematic SL mapping abilities in human cells. Recent high-throughput screening efforts hold promise for expanding SL treatments, allowing unbiased target exploration across the genome. Genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) and RNA interference-based genetic screens, including those from the Cancer Dependency Map Project (DepMap), OnTarget, and Project DR","cbCaik70SupxJS4j","https://ap.wps.com/l/cbCaik70SupxJS4j","pdf",1426345,13,"English","# Background\n# Identification strategy using genetic screens\n## Mutual exclusivity evaluation\n## Drug repurposing via drug sensitivity integration\n# Pharmacological versus genetic perturbation differences\n# Implications for precision oncology and future target mapping\n## High-throughput SL mapping approaches","[{\"question\":\"What is the core idea behind synthetic lethality in cancer therapy?\",\"answer\":\"Synthetic lethality targets a genetic interaction where loss of either gene alone is tolerated, but combined disruption causes cell death. In oncology, this is often implemented by inhibiting a protein that is lethal only in cancer cells carrying a specific loss-of-function alteration.\"},{\"question\":\"How were clinically relevant synthetic lethal interactions identified in the study?\",\"answer\":\"Genome-wide CRISPR/Cas9 knockout viability screens from the Cancer Dependency Map were analyzed, and clinical relevance was assessed in patient tumors using mutual exclusivity patterns.\"},{\"question\":\"Why do pharmacological inhibitors often fail to match CRISPR knockout effects?\",\"answer\":\"The study finds that only a small fraction of drugs induce effects similar to genetic knockout of matched targets. This discrepancy indicates fundamental differences between pharmacological and genetic perturbations in cancer models.\"}]","Challenges and opportunities for oncology drug repurposing informed by synthetic lethality | PDF",1790180142,33,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1b5af70dd2a4b141c44a84cf3352a586.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/625e4fd118aeac4299d82db569714a29.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c6ceeed00460e1240622f3128432d363.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bdb28574e1ad21162e70f23276084dd1.webp",980,1301]